E.Coli research to get €2 million EU investment

By Admin
Over €2 million, equal to $3 millionwill be invested into research of a new E.Coli strain by the European Union (EU). Approximately 4,000 European...

Over €2 million, equal to $3 million will be invested into research of a new E.Coli strain by the European Union (EU).

Approximately 4,000 Europeans were infected with the new strain of E.Coli earlier this year and 51 people died.

The outbreak of the food-borne bacteria caused huge financial losses to vegetable farmers across Europe after it was linked to cucumbers and other EU vegetables.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

Russia imports approximately €600 million worth of EU vegetables a year but it banned such activities on June 2 after they were suspected of carrying the E.Coli virus.

The source of the E.Coli outbreak was eventually indentified as being Egyptian fenugreek seeds and vegetable farmers across Europe are now hoping to receive €227 million in compensation.

The EU now wants to “get as full a scientific picture as possible” of the strain to help organise effective preventions and responses in the future.

The investment is part of the €12 million project designed to reinforce Europe’s ability to outbreaks of this nature.

In a statement the European Commission said: “the research will focus on ways to prevent future epidemics and deal with new outbreaks.”

Share

Featured Articles

Latest Apple Devices to Address Sleep Apnea & Hearing Health

Apple AirPods Pro hearing health features are approved by FDA, while Apple Watch will also offer sleep apnea detection features

Grifols & Orange Business Launch Egypt Plasma Project

Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt

Healthcare business roundup: Eli Lilly, Novo Nordisk, Aspen

Eli Lilly's experimental cardiovascular drug ‘promising’; Aspen Pharmacare to manufacture mpox vaccines; Novo Nordisk says Ozempic shortage ‘worsening’

Global Health Funding 'Facing Post-Pandemic Challenges'

Digital Healthcare

The Merck Group: Pharma's History & Innovation in India

Medical Devices & Pharma

How CVS Health is Rising to the Omnichannel Challenge

Procurement & Supply Chain